What is the recommended diagnostic work‑up and initial management for a 74‑year‑old female presenting with severe pulmonary hypertension?

Diagnostic Work-Up and Initial Management for Severe Pulmonary Hypertension in a 74-Year-Old Female

This patient requires immediate comprehensive diagnostic evaluation at a pulmonary hypertension expert center with expedited referral given the severity of disease, followed by risk stratification to determine whether she needs initial combination therapy including intravenous prostacyclin analogues or alternative treatment strategies. 1

Immediate Diagnostic Work-Up

Laboratory and Serologic Testing

• Complete blood count, comprehensive metabolic panel, thyroid function tests (TSH), and NT-proBNP to assess for contributing factors and prognostic markers 1
• Hepatitis serologies, HIV testing, and autoimmune screening (ANA initially, followed by anti-dsDNA, anti-Scl-70, anti-centromere, anti-RNP, anti-SSA, anti-SSB if ANA positive) to identify secondary causes 1
• Hypercoagulable panel if thromboembolic disease is suspected 1

Cardiovascular and Pulmonary Imaging

• Electrocardiogram and chest radiograph to identify right ventricular strain patterns and cardiopulmonary comorbidities 1
• Echocardiography with bubble study as the critical initial diagnostic tool to estimate pulmonary pressures and assess right ventricular function 1, 2
• Ventilation/perfusion (V/Q) scan is essential to exclude chronic thromboembolic pulmonary hypertension (CTEPH), as this requires different management 1
• CT angiogram or non-contrast chest CT to evaluate for parenchymal lung disease and thromboembolic disease, though V/Q scanning remains superior for CTEPH diagnosis 1

Functional Assessment

• Six-minute walk test to establish baseline functional capacity 1
• Complete pulmonary function tests to identify underlying lung disease, noting that some patients with substantial parenchymal disease may have pseudo-normalized lung function 1
• Sleep apnea evaluation as sleep-disordered breathing is a common contributing factor 1

Definitive Hemodynamic Assessment

• Right heart catheterization (RHC) is mandatory for definitive diagnosis and should only be performed after completing the above work-up to fully characterize the disease phenotype before initiating therapy 1, 3
• RHC confirms pulmonary hypertension (mean PAP >20 mmHg) and distinguishes pre-capillary PH (PAWP ≤15 mmHg, PVR >2 Wood Units) from post-capillary or combined PH 3
• Acute vasoreactivity testing during RHC is critical for idiopathic, heritable, or drug-induced PAH to identify calcium channel blocker responders 1

Risk Stratification

Assess WHO Functional Class and high-risk features including heart rate >110 bpm, systolic blood pressure <90 mmHg, low urine output, rising lactate levels, and evidence of right heart failure 1

High-Risk Indicators (WHO FC IV):

• Severe right ventricular dysfunction on echocardiography
• Markedly elevated NT-proBNP
• Syncope or near-syncope
• Signs of end-organ hypoperfusion 1

Initial Management Strategy

For High-Risk Patients (WHO FC IV):

Initial combination therapy including intravenous prostacyclin analogues should be started immediately, with IV epoprostenol prioritized as it has demonstrated mortality reduction in high-risk PAH patients even as monotherapy. 1

• Consider early referral for lung transplantation evaluation at this stage given the severity 1
• If hemodynamically unstable (HR >110, SBP <90 mmHg, low urine output, rising lactate), ICU admission is recommended with inotropic support for hypotension 1

For Low-to-Intermediate Risk Patients (WHO FC II-III):

• If vasoreactive on acute testing (idiopathic/heritable/drug-induced PAH only): High-dose calcium channel blocker therapy 1
• If non-vasoreactive: Initial oral combination therapy with ambrisentan plus tadalafil is superior to monotherapy for delaying clinical failure 1
• Alternative initial combination strategies may be considered based on local availability and expertise 1

Critical Contraindication:

The combination of riociguat and PDE-5 inhibitors is absolutely contraindicated 1

Sequential Management for Inadequate Response

If inadequate clinical response occurs (defined by worsening WHO functional class, declining six-minute walk distance, rising NT-proBNP, or clinical worsening events):

• Escalate to sequential double or triple combination therapy 1
• List for lung transplantation after inadequate response to maximal medical therapy 1
• Balloon atrial septostomy may be considered as a palliative or bridging procedure in patients deteriorating despite maximal therapy, though this carries significant risk 1

Key Pitfalls to Avoid

• Do not start PAH-specific therapy before completing the diagnostic work-up, as this can lead to inappropriate treatment if the patient has Group 2 (left heart disease) or Group 3 (lung disease) PH, where these therapies are contraindicated 1
• Do not delay referral to a PH expert center – early referral is critical for optimal outcomes, particularly in patients with suspected PAH or CTEPH 4, 5
• Avoid hypoxia and hypercarbia in acute management, as these worsen pulmonary vasoconstriction 6
• Maintain right ventricular preload – aggressive diuresis can be catastrophic in RV failure 6